Brief Title
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Official Title
A Phase I Study of SJG-136 in Patients With Advanced Leukemia
Brief Summary
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic lymphocytic leukemia. Drugs used in chemotherapy, such as SJG-136, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Detailed Description
OBJECTIVES: I. Establish the maximum tolerated dose of SJG-136 in patients with relapsed or refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) myelodysplastic syndrome (MDS), chronic myelogenous leukemia in blastic phase (CML-BP), or chronic lymphocytic leukemia (CLL). II. Determine dose-limiting toxicities and pharmacokinetics of this drug in these patients. OUTLINE: This is a dose-escalation study. Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)
Condition
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Intervention
SJG-136
Study Arms / Comparison Groups
Arm I
Description: Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
25
Start Date
December 2005
Primary Completion Date
February 2009
Eligibility Criteria
Inclusion Criteria: - Diagnosis of 1 of the following hematologic malignancies: - Acute myeloid leukemia - Acute lymphoblastic leukemia - Myelodysplastic syndromes - Chronic myelogenous leukemia in blastic phase - Chronic lymphocytic leukemia - Relapsed or refractory disease - No immediately available, potentially curable options (e.g., stem cell transplantation) available - Bilirubin normal (unless elevated due to Gilbert's syndrome) - HIV positivity allowed provided CD4 counts are normal with no AIDS-defining disease - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No uncontrolled intercurrent illness including, but not limited to, any of the following: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness or social situations that would limit study compliance - Recovered from prior therapy - ECOG performance status =< 2 - SGOT and SGPT =< 2.5 times upper limit of normal (ULN) - Creatinine normal OR creatinine clearance >= 60 mL/min - Primary resistance (i.e., failed to achieve a complete remission [CR] to a standard induction regimen) or relapsed after achievement of a CR. - Must have documented failure to last cytotoxic regimen prior to study entry. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - No known CNS disease - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to SJG-136 - More than 7 days since radiotherapy - No concurrent combination antiretroviral therapy for HIV-positive patients - No other anti-leukemia agents except hydroxyurea =< 5 grams/day =< 14 days prior to and during first course of treatment to control blood counts
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Farhad Ravandi-Kashani, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00301769
Organization ID
NCI-2009-00100
Secondary IDs
NCI-2009-00100
Responsible Party
Sponsor
Study Sponsor
National Cancer Institute (NCI)
Study Sponsor
Farhad Ravandi-Kashani, Principal Investigator, M.D. Anderson Cancer Center
Verification Date
September 2013